- Home
- OFIX vs ZURA Comparison
OFIX vs ZURA Comparison
Compare OFIX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OFIX | ZURA |
|---|---|---|
| Founded | 1987 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 521.8M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | OFIX | ZURA |
|---|---|---|
| Price | $11.67 | $4.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $17.25 | $13.00 |
| AVG Volume (30 Days) | 265.3K | ★ 637.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $10.25 | $0.99 |
| 52 Week High | $16.99 | $7.25 |
Technical Indicators
Market Signals| Indicator | OFIX | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 35.72 |
| Support Level | $10.94 | $4.36 |
| Resistance Level | $13.96 | $5.82 |
| Average True Range (ATR) | 0.57 | 0.40 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 26.87 | 22.22 |
Price Performance
Historical ComparisonAbout OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.